Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381372 | 0.86 | SRD5A2 (0.62) | FOLH1KMT2ANR4A2SRD5A2AKR1C3 | |
| SCHEMBL20354326 | 0.85 | LOXL2 (0.56) | FOLH1USP2TP53KDM4EALDH1A1 | |
| SCHEMBL1787541 | 0.84 | USP2 (0.69) | USP2TP53KDM4EKMT2ASRD5A2 | |
| SCHEMBL13381194 | 0.82 | SRD5A2 (0.62) | FOLH1SRD5A2 | |
| Isophthalic Acid SCHEMBL1250697 | 0.80 | ALDH1A1 (0.67) | KDM4EKMT2ANR4A2AKR1C3ALDH1A1 | |
| SCHEMBL10561446 | 0.80 | PIK3CA (0.67) | FOLH1KDM4EKMT2AALDH1A1ALOX15 | |
| SCHEMBL29382329 | 0.78 | FOLH1 (0.66) | FOLH1NR4A2 | |
| SCHEMBL2707508 | 0.78 | FOLH1 (0.66) | FOLH1NR4A2 | |
| SCHEMBL4861257 | 0.78 | TSHR (0.70) | FOLH1KDM4EKMT2ANR4A2AKR1C3 | |
| SCHEMBL7129795 | 0.78 | MEN1 (0.62) | USP2TP53KMT2ASRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1633724-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FOLH1 2878/4885USP2 3626/4885TP53 4517/4885 |
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FOLH1 2901/4885USP2 3472/4885TP53 4476/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FOLH1 2901/4885USP2 3472/4885TP53 4476/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FOLH1 2901/4885USP2 3472/4885TP53 4476/4885 |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | FOLH1 2663/4885USP2 2724/4885TP53 1824/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FOLH1 2878/4885USP2 3626/4885TP53 4517/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FOLH1 2878/4885USP2 3626/4885TP53 4517/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FOLH1 2901/4885USP2 3472/4885TP53 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.